, Tracking Stock Market Picks
Enter Symbol:
Sarepta Therapeutics Inc (SRPT) [hlAlert]

up 186.17 %

Sarepta Therapeutics Inc (SRPT) rated Buy by ThinkEquity

Posted on: Monday,  Aug 27, 2012  10:25 AM ET by ThinkEquity

ThinkEquity rated Buy Sarepta Therapeutics Inc (NASDAQ: SRPT) on 08/27/2012. Previously ThinkEquity rated Buy Sarepta Therapeutics Inc (NASDAQ: SRPT) on 10/21/2010.,
when the stock price was $12.66. Since then, Sarepta Therapeutics Inc has gained 186.18% as of 01/19/2016's recent price of $36.23.
If you would have followed the previous ThinkEquity's recommendation on SRPT, you would have gained 186.17% of your investment in 1916 days.

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI's NEUGENE-based ESPRIT technology will initially be applied to potential treatments for Duchenne muscular dystrophy.

Research is at the core of everything we do at ThinkEquity, and we're passionate about it. Employing a disciplined and rigorous process, we scrutinize the spectrum of forces at play in the growth sectors we cover. Starting with a top down analysis, we look closely at the megatrends and industry drivers that create opportunities for innovative companies. We then allocate our resources based on a long-range research roadmap that leads to deep domain expertise and a close working knowledge of the technologies, products, services and people that populate the growth sector landscape. In short, the sum result of the ThinkEquity research process is to identify and affiliate ourselves with the fastest growing private and public companies within our domain verticals.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/27/2012 10:25 AM Buy
as of 12/31/2012
1 Week down  -5.74 %
1 Month down  -18.88 %
3 Months up  53.18 %
1 YTD up  428.66 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/16/2011 1:33 PM Buy
12.30 24.00
10/21/2010 8:25 AM Buy
12.66 21.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy